Which has preferable valuation and earnings, NVCR or LQDA?

Liquidia has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.74 -$136.23M -$1.53 N/A Liquidia $158.32M 42.20 -$68.92M $0.14 536.57

Is NVCR or LQDA more profitable?

Liquidia has a net margin of 7.74% compared to NovoCure's net margin of -25.66%. Liquidia's return on equity of 46.82% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Liquidia 7.74% 46.82% 7.06%

Does the media refer more to NVCR or LQDA?

In the previous week, Liquidia had 10 more articles in the media than NovoCure. MarketBeat recorded 14 mentions for Liquidia and 4 mentions for NovoCure. NovoCure's average media sentiment score of 1.14 beat Liquidia's score of 0.38 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 1 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NVCR or BLCO more profitable?

Bausch + Lomb has a net margin of -4.21% compared to NovoCure's net margin of -25.66%. Bausch + Lomb's return on equity of 3.60% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Bausch + Lomb -4.21% 3.60% 1.69%

Do analysts prefer STVN or NVCR?

NovoCure has a consensus price target of $25.67, indicating a potential upside of 65.81%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00 NovoCure 1 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.29

Which has preferable valuation & earnings, STVN or NVCR?

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Stevanato Group €1.34B 3.90 €158.21M €0.59 29.28 NovoCure $655.35M 2.74 -$136.23M -$1.53 N/A

Does the media favor STVN or NVCR?

In the previous week, Stevanato Group had 3 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for Stevanato Group and 4 mentions for NovoCure. NovoCure's average media sentiment score of 1.14 beat Stevanato Group's score of -0.27 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Stevanato Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, NVCR or LIVN?

NovoCure has higher earnings, but lower revenue than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.74 -$136.23M -$1.53 N/A LivaNova $1.39B 3.29 -$242.47M $1.95 42.59

Is NVCR or LIVN more profitable?

LivaNova has a net margin of 7.48% compared to NovoCure's net margin of -25.66%. LivaNova's return on equity of 16.48% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% LivaNova 7.48% 16.48% 7.59%

Does the media refer more to NVCR or LIVN?

In the previous week, NovoCure had 1 more articles in the media than LivaNova. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for LivaNova. NovoCure's average media sentiment score of 1.14 beat LivaNova's score of 0.72 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, NVCR or NVST?

Envista has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NovoCure $655.35M 2.74 -$136.23M -$1.53 N/A Envista $2.72B 1.61 $47M $0.41 65.78

Is NVCR or NVST more profitable?

Envista has a net margin of 2.41% compared to NovoCure's net margin of -25.66%. Envista's return on equity of 7.11% beat NovoCure's return on equity. Company Net Margins Return on Equity Return on Assets NovoCure -25.66% -50.82% -16.48% Envista 2.41% 7.11% 3.91%

NovoCure (NVCR) Competitors

$15.48 +0.05 (+0.32%)

Closing price 06/29/2026 04:00 PM Eastern

Extended Trading

$15.48 0.00 (0.00%)

As of 03:59 AM Eastern

Compare

NVCR vs. LQDA, BLCO, STVN, LIVN, and NVST

Should you buy NovoCure stock or one of its competitors? MarketBeat compares NovoCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NovoCure include Liquidia (LQDA), Bausch + Lomb (BLCO), Stevanato Group (STVN), LivaNova (LIVN), and Envista (NVST). These companies are all part of the "medical equipment" industry.

How does NovoCure compare to Liquidia?

NovoCure (NASDAQ:NVCR) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Liquidia has lower revenue, but higher earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.74	-$136.23M	-$1.53	N/A
Liquidia	$158.32M	42.20	-$68.92M	$0.14	536.57

84.6% of NovoCure shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 5.5% of NovoCure shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Liquidia has a net margin of 7.74% compared to NovoCure's net margin of -25.66%. Liquidia's return on equity of 46.82% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Liquidia	7.74%	46.82%	7.06%

In the previous week, Liquidia had 10 more articles in the media than NovoCure. MarketBeat recorded 14 mentions for Liquidia and 4 mentions for NovoCure. NovoCure's average media sentiment score of 1.14 beat Liquidia's score of 0.38 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	1 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

NovoCure has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Liquidia has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market.

NovoCure presently has a consensus price target of $25.67, indicating a potential upside of 65.81%. Liquidia has a consensus price target of $68.88, indicating a potential downside of 8.31%. Given NovoCure's higher possible upside, analysts clearly believe NovoCure is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82

Summary

Liquidia beats NovoCure on 12 of the 17 factors compared between the two stocks.

How does NovoCure compare to Bausch + Lomb?

NovoCure (NASDAQ:NVCR) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

NovoCure has higher earnings, but lower revenue than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.74	-$136.23M	-$1.53	N/A
Bausch + Lomb	$5.21B	1.14	-$360M	-$0.62	N/A

Bausch + Lomb has a net margin of -4.21% compared to NovoCure's net margin of -25.66%. Bausch + Lomb's return on equity of 3.60% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Bausch + Lomb	-4.21%	3.60%	1.69%

In the previous week, NovoCure had 4 more articles in the media than Bausch + Lomb. MarketBeat recorded 4 mentions for NovoCure and 0 mentions for Bausch + Lomb. NovoCure's average media sentiment score of 1.14 beat Bausch + Lomb's score of 0.00 indicating that NovoCure is being referred to more favorably in the media.

Company	Overall Sentiment
NovoCure	Positive
Bausch + Lomb	Neutral

NovoCure presently has a consensus target price of $25.67, indicating a potential upside of 65.81%. Bausch + Lomb has a consensus target price of $17.92, indicating a potential upside of 7.74%. Given NovoCure's stronger consensus rating and higher probable upside, analysts clearly believe NovoCure is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Bausch + Lomb	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

NovoCure has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Bausch + Lomb has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

84.6% of NovoCure shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Comparatively, 1.5% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

NovoCure beats Bausch + Lomb on 10 of the 16 factors compared between the two stocks.

How does NovoCure compare to Stevanato Group?

Stevanato Group (NYSE:STVN) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

84.6% of NovoCure shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Stevanato Group has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, NovoCure has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

NovoCure has a consensus price target of $25.67, indicating a potential upside of 65.81%. Given NovoCure's higher possible upside, analysts plainly believe NovoCure is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Stevanato Group has a net margin of 11.76% compared to NovoCure's net margin of -25.66%. Stevanato Group's return on equity of 10.27% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Stevanato Group	11.76%	10.27%	6.08%
NovoCure	-25.66%	-50.82%	-16.48%

In the previous week, Stevanato Group had 3 more articles in the media than NovoCure. MarketBeat recorded 7 mentions for Stevanato Group and 4 mentions for NovoCure. NovoCure's average media sentiment score of 1.14 beat Stevanato Group's score of -0.27 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Stevanato Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NovoCure	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stevanato Group	€1.34B	3.90	€158.21M	€0.59	29.28
NovoCure	$655.35M	2.74	-$136.23M	-$1.53	N/A

Summary

Stevanato Group beats NovoCure on 11 of the 17 factors compared between the two stocks.

How does NovoCure compare to LivaNova?

NovoCure (NASDAQ:NVCR) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

NovoCure has higher earnings, but lower revenue than LivaNova. NovoCure is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.74	-$136.23M	-$1.53	N/A
LivaNova	$1.39B	3.29	-$242.47M	$1.95	42.59

NovoCure currently has a consensus price target of $25.67, suggesting a potential upside of 65.81%. LivaNova has a consensus price target of $80.75, suggesting a potential downside of 2.78%. Given NovoCure's higher possible upside, equities analysts plainly believe NovoCure is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
LivaNova	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

84.6% of NovoCure shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 5.5% of NovoCure shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

NovoCure has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

In the previous week, NovoCure had 1 more articles in the media than LivaNova. MarketBeat recorded 4 mentions for NovoCure and 3 mentions for LivaNova. NovoCure's average media sentiment score of 1.14 beat LivaNova's score of 0.72 indicating that NovoCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NovoCure	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LivaNova has a net margin of 7.48% compared to NovoCure's net margin of -25.66%. LivaNova's return on equity of 16.48% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
LivaNova	7.48%	16.48%	7.59%

Summary

LivaNova beats NovoCure on 10 of the 16 factors compared between the two stocks.

How does NovoCure compare to Envista?

NovoCure (NASDAQ:NVCR) and Envista (NYSE:NVST) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Envista has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	2.74	-$136.23M	-$1.53	N/A
Envista	$2.72B	1.61	$47M	$0.41	65.78

NovoCure currently has a consensus target price of $25.67, indicating a potential upside of 65.81%. Envista has a consensus target price of $28.67, indicating a potential upside of 6.29%. Given NovoCure's higher possible upside, equities analysts clearly believe NovoCure is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40

NovoCure has a beta of 0.93, meaning that its share price is 7% less volatile than the broader market. Comparatively, Envista has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market.

In the previous week, NovoCure had 4 more articles in the media than Envista. MarketBeat recorded 4 mentions for NovoCure and 0 mentions for Envista. NovoCure's average media sentiment score of 1.14 beat Envista's score of 0.71 indicating that NovoCure is being referred to more favorably in the media.

Company	Overall Sentiment
NovoCure	Positive
Envista	Positive

Envista has a net margin of 2.41% compared to NovoCure's net margin of -25.66%. Envista's return on equity of 7.11% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
Envista	2.41%	7.11%	3.91%

84.6% of NovoCure shares are owned by institutional investors. 5.5% of NovoCure shares are owned by insiders. Comparatively, 1.0% of Envista shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Envista beats NovoCure on 9 of the 16 factors compared between the two stocks.

Get NovoCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVCR vs. The Competition

Export

Metric	NovoCure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.79B	$3.62B	$6.84B	$12.20B
Dividend Yield	N/A	2.21%	2.66%	6.22%
P/E Ratio	-10.12	20.93	26.02	24.37
Price / Sales	2.74	347.47	551.04	101.44
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	5.09	8.71	11.02	6.49
Net Income	-$136.23M	$23.87M	$3.57B	$336.61M
7 Day Performance	9.55%	3.59%	2.62%	1.25%
1 Month Performance	-9.15%	1.73%	0.95%	0.24%
1 Year Performance	-13.03%	69.03%	36.44%	30.16%

NovoCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVCR NovoCure	3.1711 of 5 stars	$15.48 +0.3%	$25.67 +65.8%	-14.0%	$1.79B	$655.35M	N/A	1,605	Positive News
LQDA Liquidia	2.7686 of 5 stars	$75.49 +6.2%	$67.43 -10.7%	+473.4%	$6.32B	$158.32M	539.25	50	Analyst Downgrade
BLCO Bausch + Lomb	2.465 of 5 stars	$14.90 +0.2%	$17.92 +20.2%	+34.0%	$5.31B	$5.10B	N/A	13,000
STVN Stevanato Group	3.012 of 5 stars	€16.99 +0.3%	N/A	-29.9%	€5.14B	€1.34B	28.79	6,010
LIVN LivaNova	1.819 of 5 stars	$78.71 +0.3%	$80.75 +2.6%	+81.6%	$4.31B	$1.39B	40.36	3,300

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVCR) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NovoCure (NVCR) Competitors